MedTrace Logo

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

NCT05815901 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2026-05-04

No results posted yet for this study

Summary

A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.

Conditions

Interventions

DRUG

Epaminurad 6 mg

Epaminurad 6 mg tablet

DRUG

Epaminurad 9 mg

Epaminurad 9 mg tablet

DRUG

Febuxostat 40 mg

Febuxostat 40 mg tablet

DRUG

Febuxostat 80 mg

Febuxostat 80 mg tablet

DRUG

Epaminurad 6 mg placebo

Placebo tablet

DRUG

Epaminurad 9 mg placebo

Placebo tablet

DRUG

Febuxostat 40 mg placebo

Placebo tablet

DRUG

Febuxostat 80 mg placebo

Placebo tablet

Sponsors & Collaborators

Principal Investigators

  • Won Park, MD · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-21
Primary Completion
2024-03-26
Completion
2026-04-23

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815901 on ClinicalTrials.gov